Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 1
2008 2
2009 1
2010 1
2011 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Canonico M, et al. Circulation. 2007 Feb 20;115(7):840-5. doi: 10.1161/CIRCULATIONAHA.106.642280. Circulation. 2007. PMID: 17309934 Clinical Trial.
Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism.
Simon T, Beau Yon de Jonage-Canonico M, Oger E, Wahl D, Conard J, Meyer G, Emmerich J, Barrellier MT, Guiraud A, Scarabin PY; EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Simon T, et al. J Thromb Haemost. 2006 Jan;4(1):71-6. doi: 10.1111/j.1538-7836.2005.01693.x. J Thromb Haemost. 2006. PMID: 16409454 Free article.
Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study.
Canonico M, Oger E, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Canonico M, et al. J Thromb Haemost. 2006 Jun;4(6):1259-65. doi: 10.1111/j.1538-7836.2006.01933.x. J Thromb Haemost. 2006. PMID: 16706969 Free article.
Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
Bouligand J, Cabaret O, Canonico M, Verstuyft C, Dubert L, Becquemont L, Guiochon-Mantel A, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Bouligand J, et al. Clin Pharmacol Ther. 2011 Jan;89(1):60-4. doi: 10.1038/clpt.2010.241. Epub 2010 Nov 24. Clin Pharmacol Ther. 2011. PMID: 21107315
Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Straczek C, et al. Circulation. 2005 Nov 29;112(22):3495-500. doi: 10.1161/CIRCULATIONAHA.105.565556. Epub 2005 Nov 21. Circulation. 2005. PMID: 16301339